跳转至内容
Merck

C7744

Sigma-Aldrich

溴他汀 A4

≥98% (HPLC), powder

别名:

1-(3,4,5-三甲氧基苯基)-2-(3′-羟基-4′-甲氧基苯基)乙烷 3,4,5-三甲氧基-3′-羟基-4′--甲氧基芪, 2-甲氧基-5-[(1Z)-2-(3,4,5-三甲氧基苯基)乙烯基] 苯酚, CA4

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H20O5
分子量:
316.35
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

off-white

溶解度

DMSO: >10 mg/mL

儲存溫度

−20°C

SMILES 字串

COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O

InChI

1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-

InChI 密鑰

HVXBOLULGPECHP-WAYWQWQTSA-N

一般說明

考布他汀A4属于秋水仙碱类。

應用

考布他汀A4已被用于:
  • 作为抗微管剂用于确定G2/M期异柠檬酸脱氢酶(IDH1和IDH2)蛋白的作用
  • 评估联苯CA4衍生物在2D和3D癌细胞和非癌细胞模型中的的抗增生和促凋亡特性
  • 作为微管抑制剂用于研究其对猪蛔虫L3幼虫的作用

生化/生理作用

Combretastatin A4是一种靶向肿瘤血管以抑制血管生成的血管分裂剂(VDA)。它在β-微管蛋白的秋水仙碱结合位点抑制微管蛋白聚合。它通过抑制人胃细胞中的AKT功能而具有抗肿瘤活性。被抑制的 AKT 激活引起细胞增殖下降,细胞周期停滞,在体外 迁移/侵袭和 体内 转移能力降低 。Combretastatin A4 是一种天然二苯乙烯类苯酚。
考布他汀A4是一种强效的微管靶向剂。

象形圖

Skull and crossbonesCorrosion

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

Lisa M Greene et al.
Biochemical pharmacology, 84(5), 612-624 (2012-06-19)
Recent clinical data demonstrated that the vascular targeting agent Combretastatin-A4 phosphate (CA-4P) prolonged survival of patients with advanced anaplastic thyroid cancer without any adverse side effects. However, as a single agent CA-4 failed to reduce tumour growth in the murine
Lasse Dührsen et al.
Journal of neurosurgery, 128(6), 1668-1673 (2017-07-29)
OBJECTIVE Temporal lobe epilepsy (TLE) is the most common type of pharmacoresistant focal epilepsy, for which anterior mesial temporal lobe resection (AMTLR) is a treatment option. Focal cortical dysplasia Type IIIa (FCD IIIa), a developmental lesion resulting from defects in
Julie A Sosa et al.
Surgery, 152(6), 1078-1087 (2012-11-20)
Anaplastic thyroid cancer (ATC) is an aggressive neoplasm for which a paucity of data exist about the relative role of operative procedures in disease management. The FACT trial was a randomized, controlled phase 2/3 trial assessing the safety and efficacy
Lauriane Jugé et al.
Radiology, 264(2), 436-444 (2012-06-14)
To investigate the potential value of magnetic resonance (MR) elastography and diffusion-weighted (DW) MR imaging in the detection of microstructural changes of murine colon tumors during growth and antivascular treatment. The study was approved by the regional ethics committee for
Scott L Young et al.
Expert opinion on investigational drugs, 13(9), 1171-1182 (2004-08-28)
Combretastatin A4 phosphate (CA4P) represents the lead compound in a group of novel tubulin depolymerising agents being developed as vascular targeting agents (VTAs). VTAs are drugs that induce rapid and selective vascular dysfunction in tumours. CA4P is a water-soluble prodrug

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门